Hence, PARP inhibitor AG-014699 and the suberohydroxamic acid as an HDAC inhibitor have been shown to inhibit CHD4 function and tumor growth in a mouse xenograft model of EpCAM+ hepatocellular carcinoma (Nio et al., 2015). This evidence concerns the gene CHD4 and neoplasm.